Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia
Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia
复制标题
DOI：
10.1159/000317908
复制
发表时间：
2011-01-01
期刊：
影响因子：
2.6
通讯作者：
Falcao-Reis, Fernando M.
中科院分区：
文献类型：
--
作者：
Carneiro, Angela M.;Silva, Rufino M.;Falcao-Reis, Fernando M.
目的：评估玻璃体内注射雷珠单抗治疗继发于年龄相关性黄斑变性 (AMD) 或病理性近视 (PM) 以外原因的脉络膜新生血管 (CNV) 的安全性和有效性。方法：对21只眼CNV进行回顾性多中心分析。 9 只眼睛有血管样条纹，5 只眼睛有炎性脉络膜视网膜疾病，3 只眼睛有中心性浆液性脉络膜视网膜病变，4 只眼睛有特发性 CNV。随访持续6-3个月。每月评估最佳矫正视力（BCVA）、眼相干断层扫描（OCT）和眼底检查。结果：16 只眼睛 (76%) 完成了 180 天的随访。治疗后总体 BCVA 增加了 +9.8 个字母 (p = 0.015)。 43% 的人视力提高 >= 15 个字母。观察到 OCT 中心厚度显着减少。没有出现严重视力丧失、全身或眼部副作用的病例。结论：玻璃体内注射雷珠单抗治疗与 AMD 或 PM 无关的 CNV 的短期结果令人鼓舞。对于其中一些患者来说，这种治疗可能是唯一的选择。版权所有 (C) 2010 S. Karger AG，巴塞尔
Aim: Evaluation of safety and efficacy of intravitreal ranibizumab in the treatment of choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD) or pathological myopia (PM). Methods: Retrospective and multicentric analysis of 21 eyes with CNV. Nine eyes had angioid streaks, 5 inflammatory chorioretinal diseases, 3 central serous chorioretinopathy and 4 idiopathic CNV. Follow-ups lasted 6 3 months. Best-corrected visual acuity (BCVA), ocular coherence tomography (OCT) and fundus examination were assessed monthly. Results: Sixteen eyes (76%) completed 180 days of follow-up. Overall BCVA increased by +9.8 letters with treatment (p = 0.015). Visual acuity improvements >= 15 letters occurred in 43%. A significant reduction in OCT central thickness was observed. No cases of severe visual acuity loss, systemic or ocular side effects were registered. Conclusion: Short-term results of intravitreal ranibizumab for CNV unrelated to AMD or PM are encouraging. This treatment may constitute the only option for some of these patients. Copyright (C) 2010 S. Karger AG, Basel